WO1995019952A1 - Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure - Google Patents
Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure Download PDFInfo
- Publication number
- WO1995019952A1 WO1995019952A1 PCT/EP1995/000167 EP9500167W WO9519952A1 WO 1995019952 A1 WO1995019952 A1 WO 1995019952A1 EP 9500167 W EP9500167 W EP 9500167W WO 9519952 A1 WO9519952 A1 WO 9519952A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- phenyl
- radical
- nitroxyethoxy
- Prior art date
Links
- 0 *N(*)Cc1ccc(CO[Al]*)cc1 Chemical compound *N(*)Cc1ccc(CO[Al]*)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
Definitions
- Benzylamine derivatives containing NHroxy groups and their use for the treatment of cardiovascular diseases and increased intraocular pressure
- the invention relates to benzylamine derivatives which are used in the pharmaceutical industry for the manufacture of medicaments.
- substituted nitroxy compounds are described in various ways, which are said to be suitable, for example, for the treatment of cardiovascular diseases.
- the invention relates to compounds of the formula I (see attached
- AI means 1-15C-alkylene, 5-7C-cycloalkylene or di-1-4C-alkylene-5-7C-cycloalkane, and in which
- Rl is hydrogen, 1-7C-alkyl or 3-8C-cycloalkyl
- R2 is hydrogen, 1-7C-alkyl, 3-8C-cycloalkyl or A2-Y, or wherein
- R1 and R2 together and including the nitrogen atom to which both are bound, represent an unsubstituted or substituted 5-, 6- or 7-ring heterocycle which is selected from the group consisting of pyrrolidine, piperidine, piperazine, morpholine and Homopiperazine, where
- Di - l -4C-alkyl-5-7C-cycloal kan means Y is R3, NH 2 , NH-R4 or S-R5, a substituted pyrrolidino radical is substituted by one or two identical or different substituents selected from the group consisting of 1-4C-alkyl, 1-4C-alkoxy and hydroxy, a substituted one Piperidino radical is substituted with one or two identical or different substituents selected from the group consisting of 1-4C-alkyl, 1-4C-alkoxy and hydroxy, a substituted piperazino radical can be substituted in the 2-, 3-, 5- or 6-position is substituted with a 1-4C-alkyl radical and in the 4-position with a substituent selected from the group consisting of 1-4C-alkyl, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, phenyl substituted by R6, R7 and R8, phenyl-1-4C-alkyl substituted by R
- R3 furyl, naphthyl, tetrahydronaphthyl, by -O-Al-ONO, substitutability ⁇ tes phenyl or by R6, R7 and R8 substituted phenyl bedeu ⁇ tet,
- R4 is 1-7C-alkyl or the substituents -CH 2 -CH (0H) - (CH 2 0) -Ar and
- R5 substituted by R6, R7 and R8 phenyl, substituted by R6, R7 and R8 phenyl-1-4C-alkyl, optionally substituted by halogen or 1-4C-A1kyl benzhydryl, dibenzo-5-7C-cycloalkanyl, dibenzocycloheptenyl or Benzo-pyrido-5-7C-cycloal anyl means, and in addition R6 denotes hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylcarbonyl, halogen, amino, mono- or di- (1-4C-alkyl) amino or nitro,
- R7 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, halogen or nitro,
- R8 represents hydrogen or trifluoromethyl
- p represents the number 0 or 1
- Ar denotes a completely or partially unsaturated hydrocarbon ring system which is monocyclic (with 5 to 6) or bicyclic (with 9 to 10 ring atoms) in which 1, 2 or 3 carbon atoms are substituted by heteroatoms from the group nitrogen (N), oxygen (0) or sulfur (S) can be replaced by one or two identical or different substituents from the group 1-4C-A1ky, 1-4C-alkoxy, 1-4C-A1kylthio, 1-4C-A1koxy-1-4C-alkyl , 1-4C-Alkoxy- 1-4C-alkoxy, 3-4C-alkenyl, 3-4C-alkenyloxy, 3-8C-cycloalkyl, 5-10C-cycloalkylalkoxyalkyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonylamino , Carbamoyl, carbamoyl -1-4C-alkyl, halogen, hydroxy, oxo
- 1-15C-Alkylene stands for straight-chain or branched alkylene radicals with 1 to 15 carbon atoms. Examples are methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), trimethylene (-CH 2 CH 2 CH 2 -), tetramethylene (-CH 2 CH 2 CH 2 CH 2 -), pentamethylene ( -CH 2 CH 2 CH 2 CH 2 CH 2 -), hexamethylene (-CH 2 - (CH 2 ) 4 -CH 2 -), octaethylene (-CH 2 - (CH 2 ) 6 -CH 2 -), decamethylene (-CH 2 - (CH 2 ) 8 -CH 2 -), tetradecamethylene (-CH 2 - (CH 2 ) 12 -CH 2 -), 1,2-dimethylethylene [-CH (CH 3 ) -CH ( CH 3 ) -], 1,1-dimethylethylene [-C (CH 3 ) 2 -CH 2 -], isopropy
- 5-7C-Cycloalkylene stands for cycloalkylene radicals with 5 to 7 carbon atoms. Cyclohexylene radicals are preferred, the 1,2- and 1,4-cyclohexylene radicals being mentioned, for example.
- Di-1-4C-alkylene-5-7C-cycloalkane stands for cyclic hydrocarbons with 5 to 7 carbon atoms which are substituted by two (identical or different) alkylene residues with 1 to 4 carbon atoms.
- a preferred di-1-4C-alkylene-5-7C-cycloalkane radical is the 1,4-dimethylenecyclohexane radical.
- 1-7C-A1kyl stands for straight-chain and branched alkyl radicals with 1 to 7 carbon atoms. Examples include the heptyl, hexyl, neopentyl, isopentyl, pentyl, butyl, iso-butyl, sec-butyl, tert-butyl, propyl, isopropyl, - Ethyl and the methyl radical.
- 3-8C-Cycloalkyl stands for the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl radical.
- 1-4C-A1kyl stands for straight-chain or branched alkyl radicals with 1 to 4 carbon atoms. Examples include the butyl, iso-butyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radicals.
- 1-4C-Alkoxy represents a radical which, in addition to the oxygen atom, contains one of the 1-4C-alkyl radicals mentioned above.
- the methoxy and ethoxy radicals may be mentioned, for example.
- Halogen in the sense of the present invention is bromine, chlorine and fluorine.
- 1-4C-Alkoxycarbonyl stands for a radical which, in addition to the carbonyl group, contains one of the 1-4C-alkoxy radicals mentioned above. Examples include methoxycarbonyl and ethoxycarbonyl est.
- 1-4C-Alkylcarbonyl stands for a radical which, in addition to the carbonyl group, contains one of the 1-4C-alkyl radicals mentioned above.
- the acetyl radical may be mentioned.
- dibenzo-5-7C-cycloalkanyl radicals which may be mentioned are the dibenzocyclopentyl radical, the dibenzocyclohexyl radical and in particular the dibenzocycloheptyl radical.
- the benzopyrido-5-7C-cycloalkanyl radicals which may be mentioned are the benzopyridocyclopentyl radical, the benzopyridocyclohexyl radical and in particular the benzopyridocycloheptyl radical.
- 4- Mono- or di- (1-4C-alkyl) amino stands for an amino radical which is substituted by one or two identical or different of the 1-4C-alkyl radicals mentioned above.
- the methylamino, the ethylamino, the dimethylamino, the diethylamino and the diisopropylamino radical may be mentioned.
- 1-4C-A1kylthio stands for a radical which contains one of the abovementioned 1-4C-alkyl radicals in addition to the sulfur atom.
- the methylthio radical is preferred.
- 1-4C-A1koxy-1-4C-al yl stands for one of the above-mentioned 1-4C-A1kyl radicals, which is substituted by one of the above-mentioned 1-4C-alkoxy radicals. Examples include methoxymethyl, methoxyethyl est and butoxyethyl est.
- 1-4C-Alkoxy-1-4C-alkoxy stands for one of the abovementioned 1-4C-A1k-oxy radicals which is substituted by a further 1-4C-alkoxy radical.
- the methoxyethoxy radical may be mentioned.
- 3-4C-alkenyl is, for example, 2-butenyl and especially allyl.
- 3-4C-alkenyloxy contains a 3-4C-alkenyl residue in addition to the oxygen atom.
- the allyloxy radical may be mentioned as an exemplary 3-4C alkenyloxy radical.
- 5-10C-Cycloalkylalkoxyalkyl stands for an Al oxyalkylrest, which is substituted by a Cycloalkylrest.
- the cyclopropyl methoxyethyl radical may be mentioned.
- the acetylamido radical (-NH-CO-CH 3 ) may be mentioned.
- Carbamoyl stands for the rest NH 2 -C0 ⁇ .
- Carbamoyl-1-4C-alkyl represents one of the 1-4C-A1 alkyl radicals mentioned above which is substituted by carbamoyl.
- the carbamoyl ethyl est may be mentioned as an exemplary carbamoyl-1C-alkyl radical.
- 1-4C-Alkylsulfonamido stands for a sulfonamido radical to which one of the aforementioned 1-4C-alkyl radicals is attached.
- the methylsulfonamido radical may be mentioned.
- Ureido stands for the residue -NH-C0-NH 2 .
- 3-methylureido may be mentioned as mono-1-4C-alkylureido, and 3,3-dimethylureido as di-1-4C-alkylureido.
- Exemplary mono- or di-3-8C-cycloalkylureido residues are, for example, the 3-cyclohexylureido and the 3,3-di-cyclohexylureo residue.
- 1,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, perfluoroethoxy and in particular 1,1,2 are examples of 1,2-trifluoroethoxy which are wholly or partly substituted by fluorine , 2-tetrafluoroethoxy, the trifluoromethoxy, the 2,2,2-trifluoroethoxy and the difluoromethoxy radical.
- substituted pyrrole idino radicals are the 2-methylpyrrolidino, 2,5-dimethylpyrrolidino and the 3-hydroxypyrrolidino radical.
- substituted piperidino radicals are 3-hydroxypiperidino, 2-n-propylpiperidino, 5-ethyl-2-methylpiperidino, 4-n-propylpiperidino, 4,4-dimethylpiperidino, 2,6-dimethylpiperidino -, 4-hydroxypiperidino, 2-ethyl-2-methylpiperidino, 2-methylpiperidino, 2,6-dimethylpiperidino and the 2-ethylpiperidino radical.
- substituted piperazino radicals are 4-methylpiperazino-, 4- [2- (2-trifluoromethylphenyl) ethyl] piperazino-, 4-phenylpiperazino-, 4- (2-methylphenyl) piperazino-, 4- (2,3- Dimethylphenyl) piperazino-, 4- (2-chlorophenyl) piperazino-, 4- (2-methoxyphenyl) piperazino-, 4- (2-ethoxyphenyl) piperazino-, 4- (3-chlorophenyl) piperazino-, 4- ( 4-fluorophenyl) piperazino-, 4- (4-chlorophenyl) piperazino-, 4- (4-methoxyphenyl) piperazino-, 3-methyl-4- (4-chlorophenyl) piperazino-, 3-methyl-4 - (4-chlorophenyl) piperazino, 3-methyl-4 - (4-methoxyphenyl) piperazino, 3-
- REPLACEMENT BLADE (RULE 26) pylpiperazino-, 4- (3-methylhenyl) piperazino-, 4- (3-methoxyphenyl) piperazino-, 4- (4-methylphenyl) piperazino-, 4- (2,5-dimethylphenyl) piperazino-, 4th -Benzhydrylpiperazino-, 4-n-butylpiperazino-, 4-iso-butylpiperazino-, 4-tert.-butylpiperazino-, 4- (3-trifluoromethylphenyl) piperazino-, 4- (l-phenylethyl) piperazino-, 4- (2-phenylethyl) piperazino-, 4- (2-hydroxyphenyl) piperazino-, 4- (3,4-dimethoxyphenyl) piperazino-, 4-isopropylpiperazino-, 3-methyl-4- (3-methoxyphenyl) piperazino-, 4- (4
- the substituted morpholino radical for example, is the 3,5-dimethylmorpholino radical.
- substituted hoopiperazino radicals are 4-methyl, 4-ethoxycarbonyl, 4-acetyl, 4- (2-methoxyphenyl) and 4-benzoyl homopiperazino.
- Benzhydryl radicals which are optionally substituted by halogen or 1-4C-A1-kyl are, for example, benzhydryl, bis-4,4'-fluorobenzhydryl, bis-4,4'-chlorobenzhydryl, 4-chlorobenzhydryl and the 4-methyl benzhydryl rest called.
- Exemplary phenyl radicals substituted by R6, R7 and R8 are the radicals 3, 4-di hydroxy, 3-hydroxy-4-methoxy, 3,4-dimethoxy, 2-methoxy, 2-ethoxy, 3- Methoxy, 4-methoxy, 2-hydroxy, 3-hydroxy, 4-hydroxy, 3, 4-di hydroxy, 4-acetyl, 4-fluoro, 4-chloro, 2-chloro, 3-chloro, 3,4-dichloro, 3-trifluoromethyl, 2-trifluoromethyl, 2-methyl, 3-methyl, 4-methyl, 2,3-dimethyl, 2,4-dimethyl , 3,4-dimethyl, 2,5-dimethyl, 4-nitro, 2,6-dinitro-4-trifluoromethyl and 5-chloro-2-methylaminophenyl called.
- Phenyl 4- (2-methoxyethoxy) phenyl, 2-allylphenyl, 2-acetyl-4-butyramidophenyl, 4-carbamoylmethylphenyl, 4-methylphenyl, 2-tetrahydrofurfuryloxyphenyl, 2-chloro-5-methylphenyl, 2- Acetyl-4- (3,3-diethylureido) phenyl, 2-cyclohexylphenyl, 4-hydroxy-3-carbamoylphenyl, 4- (2-methoxyethyl) phenyl, 2-methoxyphenyl, 4-nitrophenyl, 2-allyloxyphenyl, 2- Cyclopentylphenyl, 2-cyanophenyl, 4-acetamidophenyl, 4-hydroxyphenyl, 2-cyclopropylphenyl, 4-methanesulfonamidophenyl, 4- (3-cycl
- Suitable salts for the compounds of the formula I are all acid addition salts. Particular mention should be made of the pharmacologically acceptable salts of the inorganic and organic acids customarily used in galenics. Pharmacologically incompatible salts, which may initially be obtained as process products in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically acceptable salts by processes known to the person skilled in the art.
- Suitable as such are water-soluble and water-insoluble acid addition salts with acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, Maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydro ⁇ y-2-naphthoic acid, the acids in the salt production - depending on whether it is a - or multi-base acid and, depending on which salt is desired - be used in an equimolar or a different ratio.
- acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfur
- Rl and R2 together and including the nitrogen atom to which both are attached represent an unsubstituted or substituted piperazine radical, where
- A2 l-10C-alkylene means
- Y is R3, NH 2 , NH-R4 or S-R5, a substituted piperazino radical in the 4-position is substituted by a substituent selected from the group consisting of 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, picolinoyl, nicotinoyl, isonicotinoyl , Benzhydryl and the rest R4 and where further
- R3 denotes phenyl or phenyl substituted by -0-A1-0N0-
- R4 denotes the substituent -CH 2 -CH (0H) - (CH 2 0) -Ar and R5, if desired, benzhydryl or dibenzocycloheptanyl substituted by halogen or 1-4C-A1kyl , Dibenzocycloheptenyl or Benzo-pyrido-cycloheptanyl, and wherein p also means the number 1 and
- Ar is phenyl, 4- (2-methoxyethoxy) phenyl, 2-allylphenyl, 2-chloro-5-methylphenyl, 2-allyloxyphenyl, 2-cyclopentylphenyl, 2-cyanophenyl or 1-naphthyl, and the salts of these compounds.
- AI 2-10C-A1 means kylene or dimethylene cyclohexane, and wherein
- R2 is hydrogen or A2-Y, or wherein
- R1 and R2 together and including the nitrogen atom to which both are bound, represent an unsubstituted or substituted piperazine radical
- Y is R3, NH 2 , NH-R4 or S-R5, a substituted piperazino radical in the 4-position is substituted by a substituent selected from the group consisting of 1-4C-alkylcarbonyl, nicotinoyl, benzhydryl and the radical R4, and furthermore
- R3 denotes phenyl or phenyl substituted by -0-A1-ONO
- R4 denotes the substituent -CH 2 -CH (0H) - (CH 2 0) -Ar
- R5 denotes benzhydryl, benzhydryl substituted by 1-4C-A1kyl
- Ar means phenyl, 2-allyphenyl or 1-naphthyl, and the salts of these compounds.
- the invention further relates to a process for the preparation of the compounds of the formula I and their salts.
- the process is characterized in that aldehydes of the formula II (see enclosed formula sheet), in which AI has the meaning given above, with the compounds of the formula III present in the form of ammonium salts (see attached formula sheet), in which Rl and R2 have the meanings given above, reacted in the presence of sodium cyanoborohydride and, if desired, subsequently obtained compounds are converted into the salts or salts obtained into the free compounds.
- mp stands for melting point
- RT room temperature
- h hour
- Hergestel11 from N- [3- (2-Allylphenoxy) -2-hydroxypropyl] -1,8-octylenediamine and 4- (2-nitroxyethoxy) benzaldehyde in methanol according to process variant A.
- the hydrochloride of the title compound was obtained from methanol / ethanol / diethyl ether recrystallized mp of the hydrochloride: 151.1-151.7 ⁇ C.
- the compounds of the formula I have valuable properties which make them commercially viable. In particular, they represent highly effective active substances for the treatment of cardiovascular diseases and diseases of the eye which are based on increased intraocular pressure.
- the compounds of the formula I represent a desired enrichment of the prior art. Because of the nitrate groups in the molecule, the compounds of the formula I are in principle suitable for prevention and treatment of such disease states in humans which are known to be treated by organic nitrates (such as glycerol trinitrate, isosorbide-5-mononitrate or isosorbide dinitrate) or by compounds which can release nitrogen monoxide (such as molsido in) can.
- organic nitrates such as glycerol trinitrate, isosorbide-5-mononitrate or isosorbide dinitrate
- nitrogen monoxide such as molsido in
- the compounds of formula I can be used for the prevention and treatment of ischemic heart diseases (angina pectoris, heart attack), cardiac compensation disorders, (pul onal) hypertension, (cerebral) thrombosis and atherosclerosis, (peripheral) vasoconstrictions, arrhythmias, certain disorders of the gastrointestinal tract (such as achalasia, irritable bowel syndrome) and increased intraocular pressure.
- ischemic heart diseases angina pectoris, heart attack
- cardiac compensation disorders pul onal hypertension
- (cerebral) thrombosis and atherosclerosis peripheral vasoconstrictions
- arrhythmias certain disorders of the gastrointestinal tract (such as achalasia, irritable bowel syndrome) and increased intraocular pressure.
- the compounds of the formula I are notable for thromboxane-antagonistic and antiviral activity and for bronchospasmolytic properties.
- Another object of the invention is therefore a method for the treatment of mammals, in particular humans, who are suffering from one of the abovementioned diseases.
- the process is characterized in that the diseased individual is administered a therapeutically effective and pharmacologically compatible amount of one or more compounds of the formula I.
- the invention also relates to the compounds of the formula I for use in the treatment of the diseases mentioned.
- REPLACEMENT BUTT (RULE 26)
- the invention also encompasses the use of compounds of the formula I in the production of medicaments which are used to combat the diseases mentioned.
- the invention further relates to medicaments which contain one or more compounds of the formula I.
- the pharmaceuticals are produced by methods known per se and familiar to the person skilled in the art.
- auxiliaries which are suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
- solvents gel formers, suppository bases, tablet auxiliaries and other active ingredient carriers
- antioxidants dispersants, emulsifiers, defoamers, flavoring agents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins).
- the active substances can be administered orally, rectally or parenterally (in particular perlingual, buccal, intravenously or percutaneously).
- the active ingredient (s) when administered orally in a daily dose of about 0.01 to about 10, preferably 0.05 to 5 mg / kg body weight, if desired in the form of several, preferably 1 to 4 individual doses to achieve the desired result.
- similar or generally lower doses in particular when the active compounds are administered intravenously can be used. If the dosage creeps in, a lower dose is administered at the beginning of the treatment and then slowly switched to a higher dose.
- the pharmaceutical preparations can also contain one or more other pharmacologically active constituents of other groups of medicaments, such as other antihypertensives, vasodilators, alpha-1 receptor blockers, alpha- 2-receptor stimulators, beta-1 receptor blockers, beta-2 receptor stimulators, ACE inhibitors, diuretics, saluretics, alkaloids, analgesics, lipid-lowering agents, anticoagulants, anticholinergics, methylxanthines, antiarrhythmics, antihistamines, dopamine blockers etc.
- other antihypertensives such as other antihypertensives, vasodilators, alpha-1 receptor blockers, alpha- 2-receptor stimulators, beta-1 receptor blockers, beta-2 receptor stimulators, ACE inhibitors, diuretics, saluretics, alkaloids, analgesics, lipid-lowering agents, anticoagulants, anticholinergics, methylxanthines, antiarrhythmics, antihistamines, dopamine block
- the relaxing effect of the compounds to be tested on spiral strips of the pulmonary artery of the rat was determined.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15350/95A AU679834B2 (en) | 1994-01-19 | 1995-01-18 | Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure |
EP95906963A EP0740649A1 (en) | 1994-01-19 | 1995-01-18 | Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure |
JP7519335A JPH09507672A (en) | 1994-01-19 | 1995-01-18 | Nitroxy-group-containing benzylamine derivatives and their use for the treatment of cardiovascular diseases and increased intraocular pressure |
BR9506549A BR9506549A (en) | 1994-01-19 | 1995-01-18 | Benzylamine derivatives containing nitroxy groups and its application for the treatment of cardiovascular diseases as well as high internal eye pressure |
KR1019960703871A KR970700646A (en) | 1994-01-19 | 1995-01-18 | Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation |
MXPA/A/1996/002847A MXPA96002847A (en) | 1994-01-19 | 1996-07-18 | Bencilamine derivatives containing nitrorxi groups and their employment to treat cardiovascular diseases and internal ocular pressure aument |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH15794 | 1994-01-19 | ||
CH157/94-2 | 1994-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995019952A1 true WO1995019952A1 (en) | 1995-07-27 |
Family
ID=4180558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/000167 WO1995019952A1 (en) | 1994-01-19 | 1995-01-18 | Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0740649A1 (en) |
JP (1) | JPH09507672A (en) |
KR (1) | KR970700646A (en) |
CN (1) | CN1143950A (en) |
AU (1) | AU679834B2 (en) |
BR (1) | BR9506549A (en) |
CA (1) | CA2181581A1 (en) |
WO (1) | WO1995019952A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045479A1 (en) * | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
US8450527B2 (en) | 2007-11-01 | 2013-05-28 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US9447078B2 (en) | 2012-01-20 | 2016-09-20 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
US10471027B2 (en) | 2009-07-02 | 2019-11-12 | Acucela, Inc. | Pharmacology of visual cycle modulators |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010328230B2 (en) * | 2009-12-07 | 2016-06-02 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
CN104994845B (en) * | 2012-10-23 | 2017-11-17 | 尼科斯科学爱尔兰公司 | Quinonyl Nitric oxidedonating compounds for ophthalmic applications |
TR201802211T4 (en) * | 2013-01-18 | 2018-03-21 | Cardioxyl Pharmaceuticals Inc | Nitroxyl donors with improved therapeutic index. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0034461A1 (en) * | 1980-02-13 | 1981-08-26 | Kowa Company, Ltd. | Aromatic aminoethanol compounds and salts thereof, pharmaceutical compositions comprising them and processes for their production |
EP0359335A2 (en) * | 1988-09-15 | 1990-03-21 | Cedona Pharmaceuticals B.V. | Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance |
WO1992004337A1 (en) * | 1990-09-05 | 1992-03-19 | Cedona Pharmaceuticals Bv | Thiazolidin derivatives |
-
1995
- 1995-01-18 WO PCT/EP1995/000167 patent/WO1995019952A1/en not_active Application Discontinuation
- 1995-01-18 AU AU15350/95A patent/AU679834B2/en not_active Expired - Fee Related
- 1995-01-18 BR BR9506549A patent/BR9506549A/en not_active Application Discontinuation
- 1995-01-18 JP JP7519335A patent/JPH09507672A/en active Pending
- 1995-01-18 EP EP95906963A patent/EP0740649A1/en not_active Withdrawn
- 1995-01-18 KR KR1019960703871A patent/KR970700646A/en not_active Application Discontinuation
- 1995-01-18 CN CN95192048A patent/CN1143950A/en active Pending
- 1995-01-18 CA CA002181581A patent/CA2181581A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0034461A1 (en) * | 1980-02-13 | 1981-08-26 | Kowa Company, Ltd. | Aromatic aminoethanol compounds and salts thereof, pharmaceutical compositions comprising them and processes for their production |
EP0359335A2 (en) * | 1988-09-15 | 1990-03-21 | Cedona Pharmaceuticals B.V. | Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance |
WO1992004337A1 (en) * | 1990-09-05 | 1992-03-19 | Cedona Pharmaceuticals Bv | Thiazolidin derivatives |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
US9458088B2 (en) | 2007-10-05 | 2016-10-04 | Acucela Inc. | Alkoxy compounds for disease treatment |
US7982071B2 (en) | 2007-10-05 | 2011-07-19 | Acucela Inc. | Alkoxy compounds for disease treatment |
US11446261B2 (en) | 2007-10-05 | 2022-09-20 | Acucela Inc. | Alkoxy compounds for disease treatment |
WO2009045479A1 (en) * | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
US8829244B2 (en) | 2007-10-05 | 2014-09-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
US8981153B2 (en) | 2007-10-05 | 2015-03-17 | Acucela Inc. | Alkoxy compounds for disease treatment |
US8993807B2 (en) | 2007-10-05 | 2015-03-31 | Acucela Inc. | Alkoxy compounds for disease treatment |
US10639286B2 (en) | 2007-10-05 | 2020-05-05 | Acucela Inc. | Alkoxy compounds for disease treatment |
US9079825B2 (en) | 2007-10-05 | 2015-07-14 | Acucela Inc. | Alkoxy compounds for disease treatment |
US10188615B2 (en) | 2007-10-05 | 2019-01-29 | Acucela Inc. | Alkoxy compounds for disease treatment |
US9737496B2 (en) | 2007-10-05 | 2017-08-22 | Acucela Inc. | Alkoxy compounds for disease treatment |
US8716529B2 (en) | 2007-11-01 | 2014-05-06 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US9452153B2 (en) | 2007-11-01 | 2016-09-27 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US9056849B2 (en) | 2007-11-01 | 2015-06-16 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US8450527B2 (en) | 2007-11-01 | 2013-05-28 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US10471027B2 (en) | 2009-07-02 | 2019-11-12 | Acucela, Inc. | Pharmacology of visual cycle modulators |
US9447078B2 (en) | 2012-01-20 | 2016-09-20 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
Also Published As
Publication number | Publication date |
---|---|
AU679834B2 (en) | 1997-07-10 |
AU1535095A (en) | 1995-08-08 |
CA2181581A1 (en) | 1995-07-20 |
EP0740649A1 (en) | 1996-11-06 |
BR9506549A (en) | 1997-10-14 |
JPH09507672A (en) | 1997-08-05 |
CN1143950A (en) | 1997-02-26 |
MX9602847A (en) | 1997-12-31 |
KR970700646A (en) | 1997-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1470115C3 (en) | N- (1-Arylalkyl-4-piperidyl) -Narylamides, their acid addition salts and process for their preparation | |
US3900481A (en) | Derivatives of pyrrolidine and piperidine | |
JP2978967B2 (en) | Novel piperazine derivative, method for producing the same, and composition containing the same | |
US4001422A (en) | 4-aminoquinazoline cardiac stimulants | |
WO2001089528A1 (en) | Thiourea derivatives of dihydropyridine npy antagonists | |
EP0176956A2 (en) | Diaryl derivatives | |
DE2428858A1 (en) | 1,3-DISUBSTITUTED 2,4 (1H, 3H) QUINAZOLINE DERIVATIVES | |
US4539322A (en) | Dihydropyridine derivatives and their use in treating heart conditions and hypertension | |
AT399338B (en) | NEW SUBSTITUTED BENZAMIDES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE BENZAMIDES | |
EP0260675A1 (en) | 4-[N-(substituted)-aminophenyl]-substituted 1,4-di-(hydro)-pyridine derivatives, process for their preparation and medicaments containing them | |
EP0296316A1 (en) | 1,4-Dihydropyridine enantiomers | |
WO1995019952A1 (en) | Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure | |
US4556656A (en) | 2-Benzoxepins | |
EP0123112A2 (en) | Chromone- and thiochromone-substituted 1,4-dihydropyridines, processes for their preparation and their use in pharmaceutical preparations | |
DE3311003A1 (en) | CHROMON AND THIOCHROMONE SUBSTITUTED 1,4-DIHYDROPYRIDIN LACTONE, SEVERAL PROCESSES FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS | |
DE3900028A1 (en) | AT THE PHENYL REST, HALOGEN AND / OR ALKYL AND / OR ALKOXY OR METHYLENDIOXYSUBSTITUTED, 5,5-DI- (METHYL) -3- (PHENYLVINYL) -1- (SUBSTITUTED AMINO-ALKOXY-IMINO) -CYCLOHEX-2-END DERIVATIVES , PROCESS FOR THEIR MANUFACTURE AND THE MEDICAMENTS CONTAINING THEREOF | |
EP0123700A1 (en) | Substituted picolinic acids, processes for their preparation, their use, and pharmaceutical preparations containing them | |
DD297813A5 (en) | PROCESS FOR THE PREPARATION OF DIHYDROPYRIDINAMIDES | |
EP0575782A1 (en) | Phenyl-1,2,5-oxadiazole-carbonamide-2-oxides for the treatment of cardiovascular disorders, in particular erectile dysfunction | |
WO1987006579A1 (en) | New amines and ethers | |
EP0244595A2 (en) | Dihydropyridine derivatives, process for their preparation and their use as pharmaceutical compounds | |
EP0731801B1 (en) | Substituted aminoalkylaminopyridines | |
DE3239573A1 (en) | Substituted picolinic acids, process for their preparation, their use and medicaments containing them | |
CH648022A5 (en) | 1 (2H) -isoquinolone COMPOUNDS AND THEREOF acid-addition salts. | |
EP0205511A1 (en) | New piperazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95192048.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ EE FI HU JP KR LT LV MD MX NO NZ PL RO RU SI SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1996 676278 Country of ref document: US Date of ref document: 19960718 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2181581 Country of ref document: CA Ref document number: PA/a/1996/002847 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995906963 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 278878 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995906963 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995906963 Country of ref document: EP |